Therapeutic gene modulation

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

Retrieved on:

Thursday, July 29, 2021

Alnylam Pharmaceuticals, Therapeutic gene modulation, Biotechnology, Companies, Genzyme

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality.

Key Points:

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality.
We are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company, said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics.
Prior to Kymera, he served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation.
Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results

Retrieved on:

Wednesday, July 21, 2021

Biotechnology, General Health, Pharmaceutical, Health, Alnylam Pharmaceuticals, Therapeutic gene modulation, Biotechnology, Life sciences, Biology

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open.

Key Points:

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open.
Management will provide an update on the Company and discuss second quarter 2021 results as well as expectations for the future via conference call on Tuesday, August 3, 2021 at 8:30 am ET.
To access the call, please dial 877-312-7507 (domestic) or +1-631-813-4828 (international) five minutes prior to the start time and refer to conference ID 8870516.
An archived webcast will be available on the Alnylam website approximately two hours after the event.

Ionis to hold second quarter 2021 financial results webcast

Retrieved on:

Wednesday, July 21, 2021

Antisense RNA, Spinal muscular atrophy, Branches of biology, Huntington's disease, Ionis Pharmaceuticals, Ionis, DNA, Biology, Therapeutic gene modulation, Sense, Carlsbad, California, Biotechnology

CARLSBAD, Calif., July 21, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4th at 11:30 a.m. Eastern Time to discuss its second quarter 2021 financial results and report on pipeline and business progress.

Key Points:

CARLSBAD, Calif., July 21, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4th at 11:30 a.m. Eastern Time to discuss its second quarter 2021 financial results and report on pipeline and business progress.
A webcast replay will be available for a limited time at the same address.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology.
Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading neurological and cardiometabolic franchises.

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Retrieved on:

Tuesday, July 13, 2021

Antisense RNA, Spinal muscular atrophy, Huntington's disease, Ionis Pharmaceuticals, Ionis, Therapeutic gene modulation, Biotechnology

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.

Key Points:

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.
The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that are underserved by existing therapeutics.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series

Retrieved on:

Wednesday, June 23, 2021

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8th annual series of RNAi Roundtable webinars over the coming weeks.

Key Points:

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8th annual series of RNAi Roundtable webinars over the coming weeks.
The 2021 RNAi Roundtable schedule is as follows:
Please visit the Capella section of our website for the latest information regarding webcast dates.
By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality.
Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.

Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on:

Tuesday, June 15, 2021

Health, Pharmaceutical, Nucleic acids, Branches of biology, Biology, RNA, Therapeutic gene modulation, Molecular biology, Biotechnology, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Antisense therapy, Sanofi, RNA interference

The "Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
Major players in the Antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, and Antisense Therapeutics Ltd.
The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases.
The antisense & RNAi therapeutics market covered in this report is segmented by technology into RNA interference; antisense RNA.

Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

Retrieved on:

Thursday, June 10, 2021

Branches of biology, Biology, Therapeutic gene modulation, Antisense RNA, Life sciences, Spinal muscular atrophy, Huntington's disease, Ionis Pharmaceuticals, Ionis, Antisense therapy, Familial amyloid polyneuropathy, Amyloidosis

CARLSBAD, Calif., June 10, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies,today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.

Key Points:

CARLSBAD, Calif., June 10, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies,today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021.
Ionis' participation highlights the advancements it's made in developing novel antisense therapies for ATTR and underscores Ionis' commitment to this patient community.
A founding member of Ionis, Dr. Bennett is responsible for continuing to advance antisense technology and expand Ionis' drug discovery platform.
He will discuss the therapeutic potential of antisense therapies to address an unprecedented range of neurological diseases, with a focus on TTR amyloidosis.

Alnylam to Webcast Presentations at Upcoming June Investor Conferences

Retrieved on:

Wednesday, May 26, 2021

Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Fitness & Nutrition, Science, Clinical trials, Alnylam Pharmaceuticals, Therapeutic gene modulation, Biotechnology, Companies, LinkedIn, Life sciences

A replay will be available on the Alnylam website within 48 hours after each event.

Key Points:

A replay will be available on the Alnylam website within 48 hours after each event.
Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform.
Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.
For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam , on LinkedIn , or on Instagram .

Alnylam Announces New Advances in ATTR Amyloidosis Program

Retrieved on:

Tuesday, May 11, 2021

In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 percent with an annual subcutaneous dosing regimen.\n\xe2\x80\x9cAlnylam has a long-standing commitment to continuous innovation aimed at providing breakthrough treatment options for patients with ATTR amyloidosis.

Key Points:

In addition, the Company announces today advancement of a new pre-clinical ATTR amyloidosis program aimed at achieving highly potent and reversible TTR reduction of over 90 percent with an annual subcutaneous dosing regimen.\n\xe2\x80\x9cAlnylam has a long-standing commitment to continuous innovation aimed at providing breakthrough treatment options for patients with ATTR amyloidosis.
Patients will undergo periodic assessments for safety and TTR reduction, and efficacy assessments at months nine and 18 of the RTE.
Alnylam expects results from the RTE study in 2022; if positive, data would support a supplemental NDA (sNDA) submission to the FDA.\nThe new ATTR program announced today stems from continued innovation from Alnylam\xe2\x80\x99s RNAi therapeutics platform efforts.
Alnylam plans to present data from its IKARIA platform and ALN-TTRsc04 program at a scientific meeting in mid-2021.\n\xe2\x80\x9cOur platform team continues to discover innovations for RNAi therapeutics that we believe can deliver meaningful advances for patients.

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

Retrieved on:

Monday, May 10, 2021

Biotechnology, Branches of biology, Biology, RNA, Alnylam Pharmaceuticals, Therapeutic gene modulation, RNA interference

Prior to joining TellBio, Dr. Gandhi was General Manager at Alnylam where he effectively led cross-expertise area teams to bring forward a rare disease medicine from development to global commercialization.

Key Points:

Prior to joining TellBio, Dr. Gandhi was General Manager at Alnylam where he effectively led cross-expertise area teams to bring forward a rare disease medicine from development to global commercialization.
Earlier at Alnylam, he was responsible for building a world-class global medical affairs vision, strategy, and operational capability to launch two novel RNAi therapeutics.
\xe2\x80\x9cI am thrilled to be joining the Company as its unique technology allows for detecting live circulating tumor cells regardless of cancer type.
Under the terms of an exclusive license, Genetron will be the distributor of TellDx within greater China and will collaborate with TellBio on enhancements to the platform.